AstraZeneca ropes in Catalent gene therapy site to produce viral vectors for Covid-19 vaccine

SourceFierce Pharma
Date Published08/24/2020

Additional Reshoring Information:

If manufacturing, is the company an OEM? Yes
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2020
Domestically, the work will be done:Both
Country(ies) from which reshored:United Kingdom
City reshored to:Harmans
State(s) reshored to:MD
If relevant, work nearshored to:-
Industry(ies):Chemicals, drug substance production
Product(s) reshoredAZD 1222, viral vectors, ChAdOx1 nCoV-19
What domestic positive factors made reshoring more attractive?Infrastructure, Under-utilized capacity, Covid-19
Government Incentive dollar amount:$1.2 billion
Find Reshoring Articles